{"id":"W4390588040","doi":"10.1038/s41591-023-02703-y","title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadian Apheresis Group; Juravinski Cancer Centre; Alberta Cancer Foundation; Queen Elizabeth II Health Sciences Centre; Saskatchewan Cancer Agency; University Health Network; Ottawa Hospital; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"Genentech; McMaster University; Gilead Sciences; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; London Health Sciences Centre; Amgen; Pfizer; Dalhousie University; Hamilton Health Sciences; GlaxoSmithKline","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Neutropenia; Adverse effect; Dexamethasone; Refractory (planetary science); Oncology; Febrile neutropenia; Gastroenterology; Toxicity","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008223195,0.000328506,0.0007239298,0.0007019089,0.00006308385,0.00002748245,0.0001069231,0.0004500066,0.0004102038],"category_scores_gemma":[0.002620131,0.0002181294,0.00008980578,0.0006793654,0.0002419877,0.0001286781,0.00006766686,0.001703683,0.00004621501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002153446,"about_ca_system_score_gemma":0.0001971931,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002586082,"about_ca_topic_score_gemma":0.0001594088,"domain_scores_codex":[0.9974359,0.0001432287,0.0004757206,0.0006534806,0.0007470609,0.0005445778],"domain_scores_gemma":[0.9979334,0.001084647,0.00005447795,0.0003774945,0.00008641309,0.0004635165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2677481,0.003871906,0.03381745,0.001920824,0.001262302,0.03505757,0.002487317,5.403645e-7,0.08345271,0.0008247478,0.02363107,0.5459255],"study_design_scores_gemma":[0.7925029,0.0122321,0.06285076,0.003874413,0.0006292248,0.001652453,0.0005768489,0.004021474,0.007700359,0.0003838771,0.1129619,0.0006137404],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9511301,0.03865923,0.00003978231,0.005423643,0.0007483008,0.001525235,0.00003798176,0.0001610068,0.00227472],"genre_scores_gemma":[0.9945841,0.0009994762,0.0006701295,0.0005468551,0.00129888,0.0001006238,0.0002108085,0.00005469756,0.00153436],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5453117,"threshold_uncertainty_score":0.8895057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02616673093690118,"score_gpt":0.3845048810255943,"score_spread":0.3583381500886931,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}